Maxima Center teams up with Google on AI tool for leukemia

The Prinses Máxima Centrum for pediatric oncology of Utrecht has partnered with Google to develop 'Capricorn,' an AI tool to revolutionize leukemia treatment for children. By integrating vast public medical data with anonymized patient information, Capricorn offers personalized treatment options in moments, a task that traditionally took days. The tool–currently undergoing a testing phase–could soon assist oncologists worldwide, especially for cases unresponsive to standard therapies.

Leveraging Google’s Gemini models, Capricorn's ability to swiftly process extensive medical literature. In addition, it can integrate literature with individual patient data to help tailor treatment plans in a fraction of the time traditional methods require. This innovation is particularly crucial for children with leukemia who do not respond to existing treatments. The hope is that the AI tool will be a vital resource for oncologists globally, transforming the treatment landscape for these young patients.

Expanding AI's scope in pediatric oncology

Beyond leukemia, AI's integration into pediatric oncology at the Princess Máxima Center is being explored in various areas, including kidney tumors and brain tumor surgeries. Prof. Dr. Marry van den Heuvel-Eibrink leads machine-learning projects to improve microscopic analysis. This initiative aims to automate the classification process, limiting international discrepancies in diagnostic outcomes. By incorporating molecular data, the research seeks to unlock insights that can drive personalized treatments, enhancing predictive capabilities of treatment success.

AI transforming brain tumor surgery

Since 2024, the use of AI in determining brain tumor types during surgery at the Princess Máxima Center has drastically reduced the time needed for diagnosis. Previously, identifying the tumor type could take up to a week, but with AI's help, it can now be determined during surgery itself. Capricorn can swiftly process extensive medical literature and integrate it with individual patient data, helping tailor treatment plans in a fraction of the time traditional methods require.

This allows surgeons to adjust their surgical approach in real time, improving the potential outcomes for pediatric patients undergoing these critical procedures. Dr. Bastiaan Tops has spearheaded the integration of these AI technologies to ensure they continue evolving, promising more precise diagnostics for a broader range of tumor types in the future.

AI as a digital weapon against skin cancer

Each week in our EverydAI column, we highlight an application of AI that makes your life easier. Even if you're not an AI expert. Today: AI and skin cancer.

Google’s efforts for AI in healthcare

Google's commitment to integrating AI within healthcare is underscored by other projects, too. During its ‘The Check Up’ event, the company unveiled its latest AI for healthcare endeavors. One such initiative is the TxGemma open models collection to accelerate AI-driven drug discovery.

Furthermore, by September 2025, their updated AI Overviews feature will cover thousands of health topics in numerous languages. These developments signify a pivotal shift towards more informed, efficient healthcare practices globally, aiding clinicians and patients in navigating complex medical landscapes with ease.

Machine learning for precision treatment

Machine learning's predictive power within AI technologies is now pivotal in personalizing patient care. The Princess Máxima Center, like many institutions, employs these innovations to handle intricate scenarios in pediatric oncology. Tools like Capricorn, by synthesizing comprehensive datasets, facilitate finely-tuned treatments. This tailored approach in leukemia care serves as an archetype for future uses in diverse cancer treatments where precise, rapid decision-making is essential, ensuring that interventions are as effective and patient-specific as possible.

Sirius Medical, a Dutch pioneer in tumor navigation technology, secures funding

Sirius Medical, a spin-off of the Netherlands Cancer Institute, secures €10 million funding.